Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk, Eli Lilly shares drop as Trump promises lower weight loss drug prices
09:23am, Friday, 17'th Oct 2025
Shares of Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY), two major pharmaceutical companies that produce weight-loss drugs, dropped sharply following comments from US president Donald Trump
Eli Lilly, Novo Nordisk Stocks Drop After Trump's Ozempic Price Comment. What to Know.
07:18am, Friday, 17'th Oct 2025
Trump told reporters late Thursday that the list price of Ozempic, which he called “the fat loss drug,” will be “much lower.”
Wall Street Breakfast Podcast: Regional Bank Worries Drag Futures Lower
06:41am, Friday, 17'th Oct 2025
Stock index futures decline as regional bank health worries weigh on sentiment, with S&P 500, Nasdaq 100, and Dow futures all in the red. Novo Nordisk (NVO) and Eli Lilly (LLY) shares drop after Trump
Novo Nordisk Shares Fall as Trump Moves to Cut Price of Weight-Loss Drugs
06:23am, Friday, 17'th Oct 2025
The president said the cost of the weight-loss drug should be much lower for Americans once negotiations with Novo Nordisk had concluded.
Novo Nordisk shares fall 5% after Trump vows weight-loss drug price cut
03:21am, Friday, 17'th Oct 2025
Novo Nordisk's shares fell around 5% in early trade on Friday after U.S. President Donald Trump said on Thursday that the price of the Danish drugmaker's best-selling weight-loss drug would be lowered
Novo Nordisk (NVO) Suffers a Larger Drop Than the General Market: Key Insights
06:46pm, Thursday, 16'th Oct 2025
Novo Nordisk (NVO) concluded the recent trading session at $56.09, signifying a -1.11% move from its prior day's close.
Trump says price of Ozempic will be lowered
05:24pm, Thursday, 16'th Oct 2025
U.S. President Donald Trump said on Thursday that the price of Novo Nordisk's best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift.
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
12:10pm, Thursday, 16'th Oct 2025
Novo Nordisk's $2.1 billion deal for Omeros' zaltenibart aims to strengthen its rare disease pipeline amid GLP-1 market headwinds.
Omeros: Novo Nordisk's Licensing Deal Sends Shares Soaring, Makes Bull Case
10:08am, Thursday, 16'th Oct 2025
Omeros Corporation's stock surged over 150% after licensing zaltenibart to Novo Nordisk for $340M upfront, plus milestones and royalties. The deal provides OMER with critical funding, alleviating bank
Can OMER stock retain Novo Nordisk driven gains over the long-term?
10:00am, Thursday, 16'th Oct 2025
Omeros Corporation (NASDAQ: OMER) opened over 150% up this morning after announcing a new licensing agreement worth up to $2.1 billion with the Bagsværd-headquartered Novo Nordisk. According to OMER'
Novo Nordisk's Akero Therapeutics Buy Targets Eli Lilly's Lead
04:15pm, Wednesday, 15'th Oct 2025
Novo Nordisk A/S NYSE: NVO recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026.
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal
02:58pm, Wednesday, 15'th Oct 2025
Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on We
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
09:41am, Wednesday, 15'th Oct 2025
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Novo Nordisk begins round of layoffs in United States, sources say
09:39am, Wednesday, 15'th Oct 2025
Drugmaker Novo Nordisk has begun a round of layoffs in its most important market, the United States, with affected staff set to be notified between this week and next, according to an email and two so
Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug
09:17am, Wednesday, 15'th Oct 2025
Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.
